Shares of Krystal Biotech Inc (NASDAQ:KRYS) have received a consensus rating of “Buy” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $55.20.
KRYS has been the subject of several research analyst reports. HC Wainwright set a $126.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research note on Monday, June 24th. Cowen reaffirmed a “buy” rating and set a $6.50 price target on shares of Daseke in a research note on Monday, May 6th. Chardan Capital set a $20.00 price target on shares of La Jolla Pharmaceutical and gave the company a “buy” rating in a research note on Monday, June 24th. Zacks Investment Research downgraded shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 9th. Finally, William Blair reaffirmed a “buy” rating on shares of Krystal Biotech in a research note on Monday, June 24th.
Shares of Krystal Biotech stock traded up $0.47 on Friday, hitting $45.70. 6,558 shares of the company traded hands, compared to its average volume of 415,743. The company has a 50 day moving average of $34.99. The company has a debt-to-equity ratio of 0.03, a quick ratio of 33.28 and a current ratio of 33.28. Krystal Biotech has a 52 week low of $14.30 and a 52 week high of $48.31. The stock has a market cap of $750.94 million, a P/E ratio of -46.92 and a beta of 0.98.
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. On average, analysts forecast that Krystal Biotech will post -1.45 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. New York State Common Retirement Fund purchased a new position in Krystal Biotech in the fourth quarter worth about $159,000. BlackRock Inc. grew its position in Krystal Biotech by 41.0% in the fourth quarter. BlackRock Inc. now owns 19,157 shares of the company’s stock worth $398,000 after acquiring an additional 5,568 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Krystal Biotech in the fourth quarter worth about $513,000. Citigroup Inc. purchased a new position in Krystal Biotech in the fourth quarter worth about $214,000. Finally, Northern Trust Corp purchased a new position in Krystal Biotech in the fourth quarter worth about $454,000. 46.05% of the stock is owned by institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: Why do companies issue convertible shares?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.